Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating relapsed or refractory classical Hodgkin lymphoma
 
Status In progress
Process STA 2018
ID number 1557

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Consultees

Companies sponsors Merck Sharp & Dohme
Others Association of Cancer Physicians
  Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  Lymphoma Action
Professional groups Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Takeda
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
21 September 2021 - 12 October 2021 Appraisal consultation
07 April 2021 Committee meeting: 1
28 July 2020 Invitation to participate
13 July 2020 Draft scope documents
19 May 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after multi-agent chemotherapy. Following on from information received from the company this appraisal has now been scheduled back into the work programme. The appraisal is anticipated to begin during late July 2020 when we will write to you about how you can get involved.
19 May 2020 In progress. Topic is in progress
07 February 2020 Suspended. Topic is now suspended
07 February 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after multi-agent chemotherapy. Please note that following on from advice received from the company and at their request NICE has suspended this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
11 June 2019 - 09 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance